Efficacy and safety of alemtuzumab, daclizumab and antithymocyte globulin in kidney transplantation

doi:10.3969/j.issn.2095-4344.2015.02.027

Abstract

Abstract:

BACKGROUND: Immunosuppressants fight against acute rejections by influencing humoral and cellular immune to suppress the immune function, and then improve patient/renal graft survival.
OBJECTIVE:To evaluate the effectiveness and safety of alemtuzumab, daclizumab and antithymocyte globulin in inducing immunosuppression in kidney transplantation.
METHODS:The randomized controlled trials of alemtuzumab or daclizumab versus ATG in kidney tranplantation published from 1966 to 2011 were enrolled by searching PubMed and EMBASE using Cochrane systematic review. We collected data and major outcomes. And a meta-analysis was conducted on homogeneous studies.
RESULTS AND CONCLUSION: A total of 9 randomized controlled trials (777 patients) about kidney transplantation were included. The meta-analysis results showed that the safety items including patient/renal graft survival and acute rejection at a follow-up of 24 months had no statistical differences among the three drugs (all P > 0.05). But there was a significant difference between the infection rates of alemtuzumab and antithymocyte globulin at 36 months of follow-up (P < 0.05). The results indicate that alemtuzumab, daclizumab and antithymocyte globulin are equally effective in inducing immunosuppression at a follow-up of 24 months in kidney transplantation. However, compared to antithymocyte globulin, alemtuzumab has a lower rate of infection at a follow-up of 36 months.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: Immunosuppressive Agents, Kidney Transplantation, Organ Transplantation

CLC Number:

R318

Wang Tao, Hao Wen-jing, Zong Huan-tao, Zhang Yong. Efficacy and safety of alemtuzumab, daclizumab and antithymocyte globulin in kidney transplantation[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(2): 305-309.

Figures/Tables 2

References

[1] Farney A, Sundberg A, Moore P, et al.A randomized trial of alemtuzumab vs. anti- thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant. 2008: 22: 41.
[2] Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation. 2009;88(6): 810.
[3] Thomas PG, Woodside KJ, Lappin JA, et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation. 2007;83(11):1509.
[4] Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364(20): 1909.
[5] Lü TM, Yang SL, Wu WZ, Tan JM. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Chin Med J (Engl). 2011;124(5):664.
[6] Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab inrenal transplantation at 24 months of follow-up. Clin Transplant. 2008;22(2):200.
[7] Ciancio G, Gaynor JJ, Roth D, et al. Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versusdaclizumab in living donor renal transplantation. Transplant Proc. 2010;42(9): 3503.
[8] Abou-Ayache R, Büchler M, Lepogamp P, et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolatemofetil, steroids and delayed cyclosporine A. Nephrol Dial Transplant. 2008;23(6):2024.
[9] Huurman VA, Kalpoe JS, van de Linde P, et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care. 2006;29(4):842.
[10] Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin- inhibitor immunosuppressive regimens: a comparative review. BioDrugs. 2005;19(1):39.
[11] 王思义,张雷.免疫抑制剂在移植领域中的应用进展[J]. 中国医师进修杂志,外科版,2006,29(9):70.
[12] 田普训,薛武军,丁小明,等.肾移植后不同免疫抑制方案的效果及不良反应的临床分析[J].中华器官移植杂志,2011,32(4): 201-204.
[13] 吴斌,柳汝明,唐尧,等.肾移植术后低剂量与常规剂量环孢素A比较进行免疫抑制治疗有效性及安全性的Meta分析[J].中国循证医学杂志,2010,10(6):683-687.
[14] 陈建中,裴继云,李景勤,等.肾移植后不同免疫抑制剂的应用研究[J].海军医学杂志,2003,24(3): 1906-198..
[15] 潘萌,孔蕴,晨畅,等. 单克隆抗体药物的研究进展[J].中国生化药物杂志, 2008,29(1): 62
[16] 吴建永,陈江华,王逸民,等.完全逆转的急性排斥反应对移植肾长期生存率的影响[J].中华泌尿外科杂志,1996,17(11):663-665.
[17] 傅耀文,周洪澜,王伟刚,等.抗CD3单克隆抗体在预防肾移植术后急性排斥反应中的作用[J]. 中国免疫医学杂志,2004,20(12): 867-872.
[18] 方针强.达珠单抗和OKT3预防肾移植术后急性排斥反应的比较[J].中国器官移植杂志,2005,25(3):155-156.
[19] 安富荣,刘刚. 抗肾移植排斥药-达利珠单抗[J]. 中国药学杂志, 2001,36(10): 713.
[20] 任吉忠,闵志廉,朱有华,等.肾移植术后应用抗胸腺细胞球蛋白的价值与前景[J].肾脏病与透析肾移植杂志, 1997,6(4):01.
[21] Park SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis. 2009;11(5):413.